Typhoid fever vaccines: Systematic review and meta-analysis of randomised controlled trials
作者： Abigail Fraser , Mical Paul , Elad Goldberg , Camilo J. Acosta , Leonard Leibovici
DOI: 10.1016/J.VACCINE.2007.08.027
关键词:
摘要: We undertook a systematic review and meta-analysis of randomised controlled trials comparing typhoid fever vaccine with any alternative or inactive agent. Trials evaluating killed whole-cell vaccines were excluded. The cumulative efficacy at 3 years for the Ty21a polysaccharide Vi similar: 51% (95%CI 36%, 62%), 55% 30%, 70%), respectively. Vi-rEPA 3.8 was higher, 89% 76%, 97%), but this has not yet been licensed use evaluated in only one trial. Adverse events mild nature most, significantly more frequent groups when compared placebo. Both currently vaccine, are safe efficacious preventing fever. Neither is registered administration to children below 2 age. Given recent finding that also affects infants, development conjugate warranted.
bristol.ac.uk
elsevier.com
sci-hub.se 参考文章(32)
Germanier R, O'Donnell S, Levine Mm, Black R, Clements Ml, Young C, Hugues T, Levine S, Rooney J, Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules. Developments in biological standardization. ,vol. 53, pp. 9- 14 ,(1983)
Zhou Wz, Shi J, Wang Zg, Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine Chinese journal of epidemiology. ,vol. 18, pp. 26- ,(1997)
A. Lackany, Y. Cerisier, N. Guerin, A. Sadek el Tantawi, M. H. Wahdan, P. Guesry, S. Sallam, P. Geoffroy, R. Germanier, Ch. Serie, A controlled field trial of liver oral typhoid vaccine Ty21a. Bulletin of The World Health Organization. ,vol. 58, pp. 469- 474 ,(1980)
Jin Yang, Camilo J Acosta, Guo-ai Si, Jun Zeng, Cui-yun Li, Da-bin Liang, R Leon Ochiai, Anne-Laure Page, M Carolina Danovaro-Holliday, Jie Zhang, Bao-de Zhou, He-zhuang Liao, Ming-liu Wang, Dong-mei Tan, Zhen-zhu Tang, Jian Gong, Jin-Kyung Park, Mohammad Ali, Bernard Ivanoff, Gui-chen Liang, Hong-hui Yang, Tikki Pang, Zhi-yi Xu, Allan Donner, Claudia M Galindo, Bai-qing Dong, John D Clemens, A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial. BMC Public Health. ,vol. 5, pp. 49- 49 ,(2005) , 10.1186/1471-2458-5-49
EA Engels, J Lau, Vaccines for preventing typhoid fever. Cochrane Database of Systematic Reviews. pp. 1261- 1261 ,(1998) , 10.1002/14651858.CD001261
Robert E. Black, Myron M. Levine, Catterine Ferreccio, Mary Lou Clements, Claudio Lanata, James Rooney, Rene Germanier, Chilean Typhoid Committee, Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Vaccine. ,vol. 8, pp. 81- 84 ,(1990) , 10.1016/0264-410X(90)90183-M
MYRON M. LEVINE, DAVID N. TAYLOR, CATTERINE FERRECCIO, Typhoid vaccines come of age. Pediatric Infectious Disease Journal. ,vol. 8, pp. 374- 381 ,(1989) , 10.1097/00006454-198906000-00010
Keith P. Klugman, Hendrik J. Koornhof, John B. Robbins, Nancy N. Le Cam, Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. ,vol. 14, pp. 435- 438 ,(1996) , 10.1016/0264-410X(95)00186-5
MyronM Levine, RobertE Black, Catterine Ferreccio, Rene Germanier, Chilean Typhoid Committee, LARGE-SCALE FIELD TRIAL OF TY21A LIVE ORAL TYPHOID VACCINE IN ENTERIC-COATED CAPSULE FORMULATION The Lancet. ,vol. 329, pp. 1049- 1052 ,(1987) , 10.1016/S0140-6736(87)90480-6
Anju Sinha, Sunil Sazawal, Ramesh Kumar, Seema Sood, Vankadara P Reddaiah, Bir Singh, Malla Rao, Abdolla Naficy, John D Clemens, Maharaj K Bhan, Typhoid fever in children aged less than 5 years The Lancet. ,vol. 354, pp. 734- 737 ,(1999) , 10.1016/S0140-6736(98)09001-1